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Abstract: Endothelin-1 levels in normal and
preeclamptic pregnant women were
determined serially to investigate the
correlation between renal function tests and
the severity markers of preeclampsia.
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2
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Plasma endothelin-1 levels were determined
in 45 serial plasma samples from 15
pregnant women who subsequently
developed preeclampsia, and in 43 plasma
samples from 25 women with uncomplicated
pregnancies retrospectively. Renal function
tests, complete blood counts, urinalysis and
blood pressure measurements were
performed during antenatal follow-ups of
these patients.
No correlations were set between plasma
endothelin-1 levels and renal function tests,

Introduction
A factor in circulation may lead to endothelial cell
damage and contribute to the development of
preeclampsia (1, 2). Plasma endothelin–1 (ET–1), which
is liberated by the endothelial cells, is the most potent
endogenous vasoconstrictor known, and its efficacy has
been shown to be potentiated in arteries without
endothelium (3, 4). To determine the importance of ET–1
in the pathophysiology of preeclampsia, we studied the
levels of ET–1 in normal and preeclamptic pregnant
women serially and investigated the correlation between
the renal function tests and the severity markers of
preeclampsia.
Materials and Methods
This study included 437 pregnant women and was
conducted between January 1993 and August 1995. The
study was approved by the ethical committee and the
participants signed a written consent form.

thrombocyte and white blood cell counts,
proteinuria, systolic and diastolic blood
pressures. There was no significant
difference between the mean plasma
endothelin-1
concentrations
of
the
preeclamptic and uncomplicated groups at all
gestational weeks but at the time of delivery.
None of the endothelin-1 values at any
gestational week differed significantly from
any other in the study group; therefore, the
risk of subsequent development of
preeclampsia could not be estimated by
plasma endothelin-1 measurements.
Key Words:
preeclampsia.
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At the time of joining the study and just before
delivery all women had blood samples taken for
determination of endothelin, urea, uric acid, creatinine
and complete blood counts. Proteinuria was also
determined by the ESBACH method. Each patient was
physically examined and blood pressure was recorded at
the initial visit. During monthly follow–ups, in addition to
blood pressure determinations, peripheral blood samples
were taken for ET–1 measurements.
Blood samples for ET–1 were collected into prechilled
test tubes containing aprotinin at a concentration of 400
kallikrein inhibitor units per milliliter and disodium
ethylenediaminetetraacetic acid at a concentration of 1.5
mg/ml for 5 milliliters of blood. All samples were
immediately centrifuged at 3000 rpm for 10 minutes and
the plasma was then removed and stored in vacutainer
tubes at –70°C until assay, for a maximum of 22 months.
Patients were classified as preeclamptic if they fulfilled
the standard criteria: absence of a history of hypertension
before pregnancy and confirmation by anamnesis with
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fundoscopic examination, blood pressure higher than
140/90 mmHg or an increase in diastolic pressure of 15
mmHg or systolic pressure of 30 mmHg compared with
blood pressures obtained before 20 gestational weeks
and proteinuria ≥0.5 gm/24 hr or ≥30 mg/dl on at least
two occasions more than 6 hours apart.

However, the blood leukocyte count was significantly
higher (P<0.01) and the blood platelet count was
significantly lower (P<0.05) in the preeclampsia group
than in the uncomplicated pregnancy group at term
(Tables 2 and 3).

Women who developed any pregnancy–related
disorder during follow–ups or had any chronic disorders
prior to gestation, multiple gestations or any actue
infection were excluded from the study. All assays were
performed in a blinded fashion by a physician who was
unaware of the diagnosis.

Table 1.

ET–1 concentrations were determined by 125I assay
system with AmerlexTM–M magnetic separation
(Amersham, Arlington Heights III) in 45 plasma samples
from 15 pregnant women who subsequently developed
preeclampsia, in 12 plasma samples from 12 preeclamptic
pregnant women who were admitted for labor but had
not any had antenatal visit and in 43 plasma samples from
25 randomly chosen women with uncomplicated
gestations according to the manufacturer’s protocol, and
evaluated retrospectively.
Results were analyzed by paired student t–test and
correlation–regression analysis.
Results
The mean age, gravidity, parity and number of
abortions are seen in Table 1. No statistically significant
difference was determined between the groups (P>0.05).
Table 2.

Age
Gravidity
Parity
Abortion
Gestational age (days)
Birth weight (gr)
APGAR (5th min)

UNCOMPLICATED
(n=25)

PREECLAMPTIC
(n=15)

27.12±4.29
2.08±1.12
0.68±0.80
0.40±0.76
270.48±9.23
3172.00±338.83
9.44±0.65

28.86±8.22
2.21±2.39
0.50±0.76
0.71±2.13
231.00±39.79
2087.14±1099.81
6.00±4.28

The renal function test results the mean systolic and
diastolic blood pressures and the mean plasma ET–1
levels for each 5–week interval by the 20th week of
gestation are seen in Tables 2 and 3. ET–1 showed no
statistically significant correlation with any of the renal
functions tests. No correlations were found between
ET–1 and the weeks of gestation, proteinuria, leukocyte
counts, systolic and diastolic blood pressures (P>0.05).
There was no significant difference between the groups in
the means of plasma ET–1 levels at all gestational weeks
(P>0.05) except just prior to delivery (P<0.05).

The liver and renal function tests, blood pressures and the plasma ET–1 levels of patients in the uncomplicated pregnancy group
(Mean±SD).

20–25
(n=13)
Systolic BP (mm Hg)
Diastolic BP (mmHg)
Proteinuria (dipstick)
ESBACH (gr/day)
Hemoglobin (gr/dl)
Leukocytes (count/cc)
Platelets (count/cc)
Urea (mg/dl)
Uric acid (mg/dl)
Creatinine (mg/dl)
ET–1 (pmol/ml)
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Characteristics of the patients (Mean±SD).

110.62±5.74
70.00±5.16
0
0
11.85±0.76
8335.38±2016.29
256545.45±51958.37
17.90±6.89
2.65±0.69
0.54±0.21
20.45±11.92

GESTATIONAL AGES (weeks)
26–30
31–35
(n=9)
(n=8)
113.33±4.92
73.33±4.92
0
0
12.73±1.22
848374±2183.47
264927.74±48663.76
17.27±3.83
2.84±0.26
0.57±0.27
20.70±5.63

111.14±7.86
71.14±6.53
0
0
11.02±0.83
8664.72±1954.28
235892.83±47374.38
16.38±3.44
3.37±1.43
0.53±0.19
22.21±6.45

At the time of delivery
(n=13)
112.92±4.64
71.25±5.37
0
0
11.74±1.23
9537.50±2579.11
279153.85±10971.88
14.27±4.27
3.84±2.16
0.51±0.21
19.44±9.29
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Table 3.

The liver and renal function tests, blood pressures and the plasma ET–1 levels of patients in the preeclampsia group (Mean±SD).

20–25
(n=15)
Systolic BP (mm Hg)
Diastolic BP (mmHg)
Proteinuria (dipstick)
ESBACH (gr/day)
Hemoglobin (gr/dl)
Leukocytes (count/cc)
Platelets (count/cc)
Urea (mg/dl)
Uric acid (mg/dl)
Creatinine (mg/dl)
ET–1 (pmol/ml)

112.50±12.58
77.50±15.00
0
0
11.50±2.45
7800.00±1131.37
216000.00±82024.39
16.00±4.24
4.45±3.18
0.66±0.49
20.84±8.89

GESTATIONAL AGES (weeks)
26–30
31–35
(n=14)
(n=11)
126.67±15.28
73.33±5.77
+++
2.95±3.18
11.37±3.25
8900.00±1555.63
178000.00±8485.28
34.00±5.66
6.80±3.82
0.75±0.49
23.25±11.01

Discussion
Although preeclampsia is a major cause of obstetric
and perinatal morbidity, the pathophysiology is still
obscure (5). The vascular endothelium is possibly involved
in the etiology of the disease (1, 2). The recently
discovered endothelium–derived peptide, ET–1, is a very
potent vasoconstrictor and plays an important role in the
course of essential hypertension (6). Many studies up to
now have demonstrated elevated plasma levels of ET–1 in
preeclampsia (7), that ET–1 may play an important role
in the pathophysiology of preeclampsia, either by acting
on vascular smooth muscle directly to induce contraction
or by increasing the formation of angiotensin II, to which
there is an increased vasopressor response in
preeclampsia (8, 9).
In our study we did not find any significant elevation
of plasma ET–1 in preeclampsia with respect to
uncomplicated gestations at all gestational weeks but at
the time of delivery (Tables 2 and 3). However, one
should keep in mind that ET–1 elicits a contractile
response in arteries with damaged endothelium, and the
severity of the damage in preeclampsia may potentiate
the effect of ET–1 (3).
In order to estimate the importance of ET–1 levels in
pregnancy, its correlation with patient characteristics is of
great value. Because it is one of the major
vasoconstrictors in the circulation, ET–1 might limit renal
blood flow, an effect which is expected to be worse in
preeclampsia. ET infusion was shown to increase vascular

165.00±21.21
101.34±5.46
++
2.78±1.83
11.35±0.35
9287.50±1283.63
194586.20±26743.23
29.46±3.68
4.96±2.78
0.46±0.37
23.56±64.68

At the time of delivery
(n=15)
156.67±32.15
109.62±6.42
+++
4.37±3.27
12.43±2.03
15333.33±4932.88
201666.67±52880.37
22.67±6.66
6.25±1.91
0.80±0.42
26.55±7.99

resistance and decrease renal perfusion and hence the
glomerular filtration rate in animal experiments (10–12).
However, Schiff et al. and Clark et al. did not find any
correlation with blood pressure, proteinuria and
gestational age (7, 12). In our study, no relationships
were found between plasma ET–1 levels and blood
pressure, proteinuria and gestational age as well as renal
function parameters, white blood cell and thrombcyte
counts in our study. This is similar to the findings of
Taylor et al., who observed no correlation of ET–1 with
gestational age, maternal age, parity, thrombocyte count,
serum creatinine, proteinuria, serum uric acid and mean
arterial pressure (13).
Although ET–1 has been suggested to play role to
take a part in the pathogenesis of preeclampsia, our
findings do not support this hypothesis. Though it
increase significantly at the time of delivery, by which
time preeclampsia had already developed, there were no
correlations between the plasma ET–1 level and the
severity of disease and the gestational week in our study.
Therefore we believe that ET–1 is not predictive in
preeclampsia and probably has a complementary rather
than an etiological role in its pathophysiology.
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